If you or someone you care for want to know how they can save when starting INBRIJA, there are options.

Below are the different savings programs that are offered to help you when starting INBRIJA.

  • RX illustration

    $0 Co-Pay Program and Ongoing Assistance

    $0 Co-Pay Program and Ongoing Assistance

    You may be eligible to receive your first prescription of INBRIJA—up to five 30-dose cartons—free with a $0 co-pay.*

    Prescription Support Services can confirm whether your insurance will cover your prescription and whether you are eligible for patient co-pay savings. If you have commercial insurance (employer-sponsored or individual) and INBRIJA is covered, you may be eligible to receive INBRIJA for as little as $30 per month, where allowed by law. Patients who participate in Medicaid, Medicare, or any other US federal healthcare program are not eligible to receive co-pay assistance.

  • Assistance illustration

    Patient Assistance Program

    Patient Assistance Program

    If you cannot afford INBRIJA, Prescription Support Services may be able to help. You may be eligible for the Patient Assistance Program, which is designed to help you get INBRIJA at no cost. Ask us for more information about the program and how to apply.

  • First aid kit illustration

    Medicare Extra Help Program

    Medicare Extra Help Program

    If you are enrolled in Medicare and have limited financial resources, you may qualify for the Medicare Extra Help program to help pay for some healthcare and prescription drug costs. Ask us for details about how to apply for the program. The Medicare Extra Help program is a federal program and is not managed by Acorda.

    Limitations and restrictions apply. The dispensing pharmacy will submit a claim to your insurance carrier. Acorda Therapeutics, Inc. will reimburse the dispensing pharmacy in the amount of your required financial contribution as determined based on your pharmacy benefit plan.

    Phone and chat icon

    If you have questions about INBRIJA or would like to speak with a Nurse Educator for additional training tips, please contact Prescription Support Services directly.

    Call toll-free 1-888-887-3447

    8 AM to 8 PM Eastern Time, Monday through Friday

Here's what to expect once your doctor prescribes INBRIJA

Prescription Support Services is here to help

Prescription Support Services works together with your doctor and a specialty pharmacy. If you have questions about how to use INBRIJA or need assistance understanding your insurance coverage, you can talk to Prescription Support Services.

  • Headset illustration

    1. You will get a call from Prescription Support Services

    After determining what kind of coverage you have, a specialist will call you to:

    • Review coverage and financial assistance options (if you are eligible)
    • Ensure that you know how to use INBRIJA
    • After determining what kind of coverage you have, a specialist will call you to
    • Review coverage and financial assistance options (if eligible)

    You must speak to the specialist who calls to get this information. Calls from your Prescription Support Services specialist will come from the phone number 1-888-887-3447.

  • Delivery truck illustration

    2. You will get your INBRIJA delivery from a specialty pharmacy

    2. You will get an INBRIJA delivery from a specialty pharmacy

    • A specialty pharmacy representative will call you to arrange payment details and delivery of INBRIJA
    • A specialty pharmacy will follow up with refills as prescribed

    You must speak to the specialty pharmacy representative who calls to confirm your shipment. Calls may come from an unrecognized phone number.

  • Outstretched hand illustration

    3. A Nurse Educator will call you to:

    3. After you have received your first carton of INBRIJA along with your Start Kit, a Nurse Educator will call you to:

    • Review device training either by phone or connecting through a video
    • Review contents of your Start Kit
    • Schedule follow-up calls

    Speaking with a Nurse Educator is highly recommended. Calls from the Nurse Education will come from 1-888-887-3447.

Head shot of nurse educator smiling

Actor portrayal.

Nurse Educators are available to support you with additional training by phone or video and to answer any questions about how to use the inhaler.

You may contact them at1-888-887-34478 AM to 8 PM ET.
Monday through Friday

INBRIJA is a prescription medicine used when needed for OFF episodes in adults with Parkinson's treated with regular carbidopa/levodopa medicine. INBRIJA does not replace regular carbidopa/levodopa medicine.

Important Safety Information

Do not use INBRIJA if you take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last 2 weeks.

Before using INBRIJA, tell your healthcare provider about your medical conditions, including:

  • asthma, chronic obstructive pulmonary disease (COPD), or any chronic lung disease
  • daytime sleepiness, sleep disorders, sleepiness/drowsiness without warning, or use of medicine that increases sleepiness, including antidepressants or antipsychotics
  • dizziness, nausea, sweating, or fainting when standing up
  • abnormal movement (dyskinesia)
  • mental health problems such as hallucinations or psychosis
  • uncontrollable urges like gambling, sexual urges, spending money, or binge eating
  • glaucoma
  • pregnancy or plans to become pregnant. It is unknown if INBRIJA will harm an unborn baby.
  • breastfeeding or plans to breastfeed. Levodopa can pass into breastmilk and it is unknown if it can harm the baby.

Tell your healthcare provider if you take:

  • MAO-B inhibitors
  • dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide)
  • isoniazid
  • iron salts or multivitamins that contain iron salts

Do not drive, operate machinery, or do other activities until you know how INBRIJA affects you. Sleepiness and falling asleep suddenly can happen as late as a year after treatment is started.

Tell your healthcare provider if you experience the following side effects:

  • falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
  • withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
  • low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
  • hallucinations and other psychosis - INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
  • unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
  • uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson's medicines may need to be changed.
  • bronchospasm - people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
  • increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
  • changes in certain lab values including liver tests

The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Do not orally inhale more than 1 dose (2 capsules) for any OFF period. Do not take more than 5 doses (10 capsules) in a day.

INBRIJA® Indication

Treats OFF periods in adults taking carbidopa/levodopa (CD/LD). INBRIJA doesn't replace CD/LD.

Important Safety Information

Don't use if you have taken a nonselective monoamine oxidase inhibitor (eg, phenelzine, tranylcypromine) within the last 2 weeks.

SEE MORE see-more